

University of the Philippines Ma

The Health Sciences Center

BIDS & AWARDS COMMITTEE 4

BAC Office, PGH Compound Taft Avenue, Manila Tel. Nos.: 8554-8400 loc. 3014/3015



NEFA No: 2021-017


PROPERTY & SUPPLY DIVISION

AUG 20 2021

AMMIN

Time:

NOTICE TO EXECUTE FRAMEWORK AGREEMENT (Notice of Award)



05 August 2021

GENACE PHARMA DISTRIBUTOR

#19 Diamond Street Greenheights Village


Sucat Parañaque City Tel Nos. : 659-7890

Attention:

MR. CHARLES E. BASUEL

Authorized Representative

Dear Mr. Basuel:



You are hereby required to provide within <u>TEN (10) DAYS</u> the performance security in the form of: (a) Cash, Certified Check, Cashier's Check, Manager's Check, Bank Draft or Irrevocable Letter of Credit confirmed by a reputable local bank at 5% of the total amount of award which amounts to <u>ONE HUNDRED THIRTY SEVEN THOUSAND NINE HUNDRED FIFTY PESOS & 00/100 (PHP137,950.00)</u> <u>ONLY</u>; or (b) 30% of the total amount of award in the form of Security Bond callable upon demand issued by any reputable surety or insurance company in the amount of <u>EIGHT HUNDRED TWENTY SEVEN THOUSAND SEVEN HUNDRED PESOS & 00/100 (PHP827,700.00) ONLY</u> to be submitted to the BAC Office, UPM-PGH. Failure to provide the performance security shall constitute sufficient ground for the cancellation of the award and forfeiture of the bid security.

PROPERTY AND SUPPLY DIVISION, PGH

Item No.	Quantity	UNIT	Item Description	UNIT COST (PHP)	TOTAL COST (PHP)
42	1,800	pc	Cyclophosphamide 500mg vial powder (IV), Cytoace	130.00	234,000.00
43	4,000	рс	Cyclophosphamide 1gm vial powder (IV), Cytoace	250.00	1,000,000.00
101	500	pc	Ifosfamide powder, 2gms vial (IV infusion), Fosfa	1,950.00	975,000.00
102	500	pc	Ifosfamide powder, 1g vial (IV infusion) , Fosfa	1,100.00	550,000.00
	Total Amount of Award			PhP2,759,00	00.00

MA. VERONICA A. COKING KEY ACCOUNT OFFICER

Sigh

TERMS AND CONDITION

1. Delivery of the goods is required as stated in the request of the end-user, commencing on the 3rd working day of notification through confirmed fax that the approved Purchase Order / Notice to Supplier (NTS) is already available for pick-up.

Delivery schedule (whichever is applicable):

- a) within seven (7) calendar days;
- b) as may be called for; c) staggered delivery within three (3) months
- > 50% of the total quantity within seven (7) calendar days and 25% each for the succeeding months

Note: The end-user has the right to adjust the quantity to be delivered depending on the actual need of the hospital.

- 2. Deliveries shall have at least one (1) year expiration date
- 3. Delivery of good with product complaint shall be put on hold until receipt of the final decision of the PGH management whether to proceed with the acceptance or to cancel/return the items.
- 4. Delivered items found to be non-formulary at any given time shall be returned to the company and a credit memo shall be issued.
- 5. Stocks delivered are subject to random sampling for testing as to quality and conformity to label. Testing fee at supplier's expense.
- 6. Sufficient stocks for one (1) year
- 7. The quantities specified are the estimated requirements during the period and may be decreased depending upon the actual need of the hospital and availability of funds. It is understood therefore that the hospital is not bound to order/purchase all the quantities/items called for in this Invitation to Bid (ITB)
- 8. All items that had been pulled out for various reasons, a credit memo shall be issued by the Contractor within one (1) month otherwise, a debit memo shall be processed by UP Manila PGH and the amount will be deducted from any amount due to Contractor.
- 9. Stocks with lot #/batch different from submitted Certificate of Analysis (COA) will be subjected to testing as to quality and conformity to label. Testing fee at supplier's expense.
- 10. Winning bidders for cytotoxic injectable drugs are required to provide one (1) spill kit per company under the first Purchase Order.
- 11. For cytotoxic injectable drugs, winning bidders are required to provide Material Safety Data Sheet (MSDS) and to submit Drug Profile to the Pharmacy Department per company under the first Purchase Order.
- 12. Failure to submit these documents shall be a ground for post-disqualification in accordance with RA 9184.
- 13. Compliance with R.A. 9184 and other applicable laws

	GERARDO D. LEGASPI, MD 分か. Director, UPM-PGH ル
	CONFORME: MA. VERONIKA A. COKING KEY ACCOUNT OFFICER
	(Signature over Printed Name)
	(Designation)
Ī	(Date)

Very truly yours,